TScan Therapeutics, Inc.
TCRX
$0.95
-$0.07-6.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 139.37% | 473.88% | 283.57% | -90.78% | -73.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 139.37% | 473.88% | 283.57% | -90.78% | -73.01% |
| Cost of Revenue | 20.66% | 21.42% | 19.84% | -16.35% | 15.48% |
| Gross Profit | -15.73% | -12.21% | -13.69% | 5.33% | -33.73% |
| SG&A Expenses | 6.28% | 17.01% | 21.90% | 30.20% | 25.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.50% | 20.43% | 20.29% | 30.84% | 17.59% |
| Operating Income | -13.58% | -13.31% | -15.55% | -71.90% | -31.82% |
| Income Before Tax | -19.48% | -16.71% | -13.22% | -82.58% | -29.96% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.48% | -16.71% | -13.22% | -82.58% | -29.96% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.48% | -16.71% | -13.22% | -82.58% | -29.96% |
| EBIT | -13.58% | -13.31% | -15.55% | -71.90% | -31.82% |
| EBITDA | -14.84% | -15.02% | -18.10% | -79.31% | -34.66% |
| EPS Basic | -12.33% | -8.88% | 4.15% | -54.30% | -16.49% |
| Normalized Basic EPS | -12.34% | -8.88% | 4.17% | -49.59% | -16.51% |
| EPS Diluted | -12.33% | -8.88% | 4.15% | -54.30% | -16.49% |
| Normalized Diluted EPS | -12.34% | -8.88% | 4.17% | -49.59% | -16.51% |
| Average Basic Shares Outstanding | 6.36% | 7.21% | 18.13% | 18.32% | 11.57% |
| Average Diluted Shares Outstanding | 6.36% | 7.21% | 18.13% | 18.32% | 11.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |